New study finds cystic fibrosis drug allows patients to safely scale back lung therapies

A new multi-site study led by researchers at CU Anschutz shows that people with cystic fibrosis (CF) who start the triple-drug therapy elexacaftor / tezacaftor / ivacaftor (ETI) can safely reduce many of their daily lung treatments while maintaining good health for years.

The study was published today in the Journal of Cystic Fibrosis.

“This is incredibly meaningful for individuals and families living with CF,” said lead author Scott Sagel, MD, PhD, professor of pediatrics-pulmonary medicine at the CU Anschutz School of Medicine and director of the University of Colorado Cystic Fibrosis Center. “For decades people with CF have spent hours every day managing their disease. Our findings show that many have stepped back from some of those time-consuming therapies thanks to ETI.”

E